Allopurinol

• 

  Subject Areas on Research

  • A randomized comparison between rasburicase and allopurinol in children with lymphoma or leukemia at high risk for tumor lysis. 
  • A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. 
  • Allopurinol hepatotoxicity is associated with human leukocyte antigen Class I alleles. 
  • Allopurinol-induced orotidinuria. 
  • Allopurinol-induced orotidinuria. A test for mutations at the ornithine carbamoyltransferase locus in women. 
  • Analysis of myocardial function in orthotopic cardiac allografts after prolonged storage in UW solution. 
  • Antiangiogenic agents protect liver sinusoidal lining cells from cold preservation injury in rat liver transplantation. 
  • Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. 
  • Clinical Pharmacogenetics Implementation Consortium guidelines for human leukocyte antigen-B genotype and allopurinol dosing. 
  • Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. 
  • Cost-effectiveness analysis of genotyping for HLA-B*5801 and an enhanced safety program in gout patients starting allopurinol in Singapore. 
  • Effect of medical management on recurrent stone formation following percutaneous nephrolithotomy. 
  • Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. 
  • Effects of leukocyte depleted blood on renal reperfusion injury in a porcine model. 
  • Efficacy of recombinant human manganese superoxide dismutase compared to allopurinol in protection of ischemic skeletal muscle against "no-reflow". 
  • Enhanced cardiac preservation with oxygenated University of Wisconsin solution. 
  • Evaluation of solutions for small intestinal preservation. Biochemical changes as a function of storage time. 
  • Experience with combined hepatic, pancreaticoduodenal, and renal procurement with UW solution. 
  • Familial hyperuricemia and renal insufficiency. 
  • HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 
  • Human leukocyte antigens and drug hypersensitivity. 
  • Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. 
  • Immunologic basis for allopurinol-induced severe cutaneous adverse reactions: HLA-B*58:01-restricted activation of drug-specific T cells and molecular interaction. 
  • Impact of donor factors and preservation on function and survival after liver transplantation. 
  • In vivo assessment of free radical activity during shock wave lithotripsy using a microdialysis system: the renoprotective action of allopurinol. 
  • Intestinal transplantation: the University of Wisconsin experience. 
  • Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. 
  • Management of leukemic hyperleukocytosis with hydration, urinary alkalinization, and allopurinol. Are cranial irradiation and invasive cytoreduction necessary? 
  • Modified LSA2-L2 treatment in 53 children with E-rosette-positive T-cell leukemia: results and prognostic factors (a Pediatric Oncology Group Study). 
  • Pharmacologic treatment of uric acid calculi. 
  • Procurement, preservation, and transport of cadaver kidneys. 
  • The current state of care in gout: Addressing the need for better understanding of an ancient disease. 
  • The predictive value of donor liver biopsies on the development of primary nonfunction after orthotopic liver transplantation. 
  • The role of allopurinol and deferoxamine in preventing pressure ulcers in pigs. 
  • The use of UW solution in clinical transplantation. A 4-year experience. 
  • Update on preservation of liver grafts. 
  • Uric acid level and allopurinol use as risk markers of mortality and morbidity in systolic heart failure. 
  • Uricase and other novel agents for the management of patients with treatment-failure gout. 
  • Use of HLA-B*58:01 genotyping to prevent allopurinol induced severe cutaneous adverse reactions in Taiwan: national prospective cohort study. 
  • Utilization of pediatric donors for pancreas transplantation. 
  • Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. 
  • Xanthine urolithiasis. 
• 

  Keywords of People

  • O'Connor, Christopher Michael, Adjunct Professor in the Department of Medicine, Medicine, Clinical Pharmacology
  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology